Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Wall Street analysts forecast that Heron Therapeutics (HRTX) will report quarterly loss of $0.03 per share in its upcoming release, pointing to a year-over-year increase of 82.4%. It is anticipated that revenues will amount to $36.4 million, exhibiting an increase of 15.8% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 25% to its current level. This demonstrates the covering analysts' collective reassessment of their initial pro ...